Charles River Set To Launch First Global CRO Preclinical Testing Center In China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Charles River Laboratories, one of the world's leading contract research organizations, is set to open a new preclinical testing facility this week in the rapidly expanding Chinese market, according to Senior VP Christopher Perkins
You may also be interested in...
Chinese FDA Shows Signs Of Loosening Up, Say Pharmaceutical Sector Leaders
SAN FRANCISCO - Roche will try to test a foreign-discovered drug in a first-in-man clinical trial in China in the next two years, according to one of the firm's top R&D officials in that country. The move would mark a huge shift in attitude at China's pharmaceutical regulatory agency, which to date only allows in-country discoveries to move into Chinese first-in-man clinical trials
Chinese FDA Shows Signs Of Loosening Up, Say Pharmaceutical Sector Leaders
SAN FRANCISCO - Roche will try to test a foreign-discovered drug in a first-in-man clinical trial in China in the next two years, according to one of the firm's top R&D officials in that country. The move would mark a huge shift in attitude at China's pharmaceutical regulatory agency, which to date only allows in-country discoveries to move into Chinese first-in-man clinical trials
U.S. Economic Crisis, Beijing’s Perks, Could Trigger Reverse Brain Drain
BEIJING - The financial meltdown and widening layoffs in the United States, combined with Beijing's injection of stimulus funds into its pharmaceutical and biotech sectors, could trigger a reverse brain drain in those sectors, according to industry insiders and investors in the U.S. and China